Lantheus Holdings, Inc
LNTHStock
$105.11+28.38%52W
Market Cap$6.80B
P/E29.12x
Div yield—
Beta-0.02
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)40.92%
Price vs S&P 500 (4W)-1.27%
VGM Score63.08
Market Capitalization$6.80B
P/E Ratio (Annual)29.12x
Earnings Surprise History
Q1 261.46est. 1.26
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.11
4.11
4.11
4.11
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LNTHLantheus Holdings, Inc | C | B | B | $105.11 |
| IDXXIdexx Laboratories Inc | D | B | C | $576.07 |
| CLDXCelldex Therapeutics, Inc | F | F | B | $35.40 |
| NEOGNeogen Corp | C | C | B | $10.33 |
| NTLAIntellia Therapeutics, Inc | D | C | C | $11.86 |
| NNNNAnbio Biotechnology Class A Ordinary Shares | F | B | F | $9.60 |
| QDELQuidelOrtho Corporation Common Stock | C | C | C | $18.24 |
| ACHVAchieve Life Sciences, Inc. | F | F | A | $5.96 |
| MYGNMyriad Genetics Inc | C | C | B | $6.19 |
| TKNOAlpha Teknova, Inc. Common Stock | C | C | B | $5.32 |
| IMDXInsight Molecular Diagnostics Inc. Common Stock | F | D | B | $4.71 |
About
Lantheus Holdings is a radiopharmaceutical company that develops and markets imaging agents and diagnostic solutions focused on oncology and precision diagnostics. Its products are used by physicians and technologists in clinical settings to identify and monitor disease. The company operates primarily in the United States, with international distribution networks in Europe, Canada, Australia, Asia-Pacific, and Latin America.